REFERENCES
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-49.
2. Scarlata GGM, Cicino C, Spagnuolo R, et al. Impact of diet and gut microbiota changes in the development of hepatocellular carcinoma. Hepatoma Res. 2024;10:19.
3. Kim TH, Kim SY, Tang A, Lee JM. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. Clin Mol Hepatol. 2019;25:245-63.
4. Kim TK, Jang HJ. Contrast-enhanced ultrasound in the diagnosis of nodules in liver cirrhosis. World J Gastroenterol. 2014;20:3590-6.
5. Ciocalteu A, Iordache S, Cazacu SM, et al. Role of contrast-enhanced ultrasonography in hepatocellular carcinoma by using LI-RADS and ancillary features: a single tertiary centre experience. Diagnostics. 2021;11:2232.
6. Duparc F, Grignon B, Bonnel F, Macchi V, Douard R. Liver anatomy: from Couinaud to the transplantation. Surg Radiol Anat. 2020;42:1405.
7. Fasel JHD. Human liver territories: think beyond the 8-segments scheme. Clin Anat. 2017;30:974-7.
9. Tyagi G, Jha RK. Portal vein variations, clinical correlation, and embryological explanation: a review article. Cureus. 2023;15:e36400.
10. Mao W, Jiang X, Cao Y, et al. A practical study of the hepatic vascular system anatomy of the caudate lobe. Quant Imaging Med Surg. 2021;11:1313-21.
11. D’Souza JC, Sultan LR, Hunt SJ, et al. B-mode ultrasound for the assessment of hepatic fibrosis: a quantitative multiparametric analysis for a radiomics approach. Sci Rep. 2019;9:8708.
12. Hirooka M, Koizumi Y, Sunago K, et al. Efficacy of B-mode ultrasound-based attenuation for the diagnosis of hepatic steatosis: a systematic review/meta-analysis. J Med Ultraso. 2022;49:199-210.
13. Uggowitzer M, Kugler C, Machan L, et al. Power Doppler imaging and evaluation of the resistive index in focal nodular hyperplasia of the liver. Abdom Imaging. 1997;22:268-73.
14. Cannella R, Giambelluca D, Pellegrinelli A, Cabassa P. Color Doppler ultrasound in portal hypertension: a closer look at left gastric vein hemodynamics. J Ultrasound Med. 2021;40:7-14.
15. Iranpour P, Lall C, Houshyar R, et al. Altered Doppler flow patterns in cirrhosis patients: an overview. Ultrasonography. 2016;35:3-12.
16. Chawla Y, Kumar S, Dhiman RK, Suri S, Dilawari JB. Duplex Doppler sonography in patients with Budd-Chiari syndrome. J Gastroenterol Hepatol. 1999;14:904-7.
17. Lee DH, Lee JY, Han JK. Superb microvascular imaging technology for ultrasound examinations: Initial experiences for hepatic tumors. Eur J Radiol. 2016;85:2090-5.
18. Shankar N, Kuo L, Krugliak Cleveland N, et al. Point-of-care ultrasound in gastroenterology and hepatology. Clin Gastroenterol Hepatol. 2025;23:1277-90.
19. Ying X, Dong S, Zhao Y, Chen Z, Jiang J, Shi H. Research progress on contrast-enhanced ultrasound (CEUS) assisted diagnosis and treatment in liver-related diseases. Int J Med Sci. 2025;22:1092-108.
20. Friedrich-Rust M, Klopffleisch T, Nierhoff J, et al. Contrast-enhanced ultrasound for the differentiation of benign and malignant focal liver lesions: a meta-analysis. Liver Int. 2013;33:739-55.
21. Goto E, Masuzaki R, Tateishi R, et al. Value of post-vascular phase (Kupffer imaging) by contrast-enhanced ultrasonography using Sonazoid in the detection of hepatocellular carcinoma. J Gastroenterol. 2012;47:477-85.
22. Huang J, Gao L, Li J, et al. Head-to-head comparison of Sonazoid and SonoVue in the diagnosis of hepatocellular carcinoma for patients at high risk. Front Oncol. 2023;13:1140277.
23. Westwood M, Joore M, Grutters J, et al. Contrast-enhanced ultrasound using SonoVue® (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2013;17:1-243.
24. Ren J, Lu Q, Fei X, et al. Assessment of arterial-phase hyperenhancement and late-phase washout of hepatocellular carcinoma-a meta-analysis of contrast-enhanced ultrasound (CEUS) with SonoVue® and Sonazoid®. Eur Radiol. 2024;34:3795-812.
25. Kang HJ, Kim JH, Yoo J, Han JK. Diagnostic criteria of perfluorobutane-enhanced ultrasonography for diagnosing hepatocellular carcinoma in high-risk individuals: how is late washout determined? Ultrasonography. 2022;41:530-42.
26. D’Onofrio M, Crosara S, De Robertis R, Canestrini S, Mucelli RP. Contrast-enhanced ultrasound of focal liver lesions. AJR Am J Roentgenol. 2015;205:W56-66.
27. Sawatzki M, Meyenberger C, Brand S, Semela D. Contrast-enhanced ultrasound (CEUS) has excellent diagnostic accuracy in differentiating focal liver lesions: results from a Swiss tertiary gastroenterological centre. Swiss Med Wkly. 2019;149:w20087.
28. Schwarze V, Marschner C, Völckers W, et al. Diagnostic value of contrast-enhanced ultrasound versus computed tomography for hepatocellular carcinoma: a retrospective, single-center evaluation of 234 patients. J Int Med Res. 2020;48:300060520930151.
29. Ghazanfar H, Javed N, Qasim A, et al. Metabolic dysfunction-associated steatohepatitis and progression to hepatocellular carcinoma: a literature review. Cancers. 2024;16:1214.
30. Chen HJ, Huang TX, Jiang YX, Chen X, Wang AF. Multifunctional roles of inflammation and its causative factors in primary liver cancer: a literature review. World J Hepatol. 2023;15:1258-71.
31. Hansmann J, Ray CE Jr
32. Beudeker BJB, Fu S, Balderramo D, et al. Validation and optimization of AFP-based biomarker panels for early HCC detection in Latin America and Europe. Hepatol Commun. 2023;7:e0264.
33. Cao J, Dong Y, Xu X, et al. LI-RADS CEUS nonradiation TRA version 2024: application on HCC patients treated with ablation treatment. Ultrasound Med Biol. 2025;51:1308-15.
34. Han K, Kim JH. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. World J Gastroenterol. 2015;21:10327-35.
35. Zhang Y, Li Q, Li L, et al. Diagnostic performance of modified contrast-enhanced ultrasound liver imaging reporting and data system in patients without risk factors for hepatocellular carcinoma: comparison with world federation for ultrasound in medicine and biology guideline. Ultrasound Med Biol. 2024;50:243-50.
36. Piscaglia F, Wilson SR, Lyshchik A, et al. American college of radiology contrast enhanced ultrasound liver imaging reporting and data system (CEUS LI-RADS) for the diagnosis of hepatocellular carcinoma: a pictorial essay. Ultraschall Med. 2017;38:320-4.
37. Terzi E, Iavarone M, Pompili M, et al.; CEUS LI-RADS Italy study group collaborators. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules. J Hepatol. 2018;68:485-92.
38. Quaia E, Alaimo V, Baratella E, et al. Effect of observer experience in the differentiation between benign and malignant liver tumors after ultrasound contrast agent injection. J Ultrasound Med. 2010;29:25-36.
39. Park HJ, Kim SY. Imaging modalities for hepatocellular carcinoma surveillance: expanding horizons beyond ultrasound. J Liver Cancer. 2020;20:99-105.
40. Melendez-Torres J, Singal AG. Early detection of hepatocellular carcinoma: roadmap for improvement. Expert Rev Anticancer Ther. 2022;22:621-32.
41. Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154:1706-18.e1.
42. Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236.
43. Tarao K, Nozaki A, Komatsu H, et al. Comparison of unenhanced magnetic resonance imaging and ultrasound in detecting very small hepatocellular carcinoma. World J Hepatol. 2021;13:699-708.
44. Mei Q, Yu M, Chen Q. Clinical value of contrast-enhanced ultrasound in early diagnosis of small hepatocellular carcinoma (≤ 2 cm). World J Clin Cases. 2022;10:8525-34.
45. Claudon M, Dietrich CF, Choi BI, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver-update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultraschall Med. 2013;34:11-29.
46. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases. Hepatology. 2018;68:723-50.
47. Sidhu PS, Cantisani V, Dietrich CF, et al. The EFSUMB guidelines and recommendations for the clinical practice of contrast-enhanced ultrasound (CEUS) in non-hepatic applications: update 2017 (long version). Ultraschall Med. 2018;39:e2-44.
48. Wang DC, Jang HJ, Kim TK. Characterization of indeterminate liver lesions on CT and MRI with contrast-enhanced ultrasound: what is the evidence? AJR Am J Roentgenol. 2020;214:1295-304.
49. Seitz K, Strobel D, Bernatik T, et al. Contrast-enhanced ultrasound (CEUS) for the characterization of focal liver lesions - prospective comparison in clinical practice: CEUS vs. CT (DEGUM multicenter trial). Parts of this manuscript were presented at the ultrasound Dreiländertreffen 2008, Davos. Ultraschall Med. 2009;30:383-9.
50. Lanka B, Jang HJ, Kim TK, Burns PN, Wilson SR. Impact of contrast-enhanced ultrasonography in a tertiary clinical practice. J Ultrasound Med. 2007;26:1703-14.
51. Enders J, Zimmermann E, Rief M, et al. Reduction of claustrophobia during magnetic resonance imaging: methods and design of the “CLAUSTRO” randomized controlled trial. BMC Med Imaging. 2011;11:4.
52. Zhang Z, Ma C, Luo Y. Diagnostic value of liver contrast-enhanced ultrasound in early hepatocellular carcinoma: a systematic review and meta-analysis. J Gastrointest Oncol. 2023;14:626-35.
53. Candita G, Rossi S, Cwiklinska K, et al. Imaging diagnosis of hepatocellular carcinoma: a state-of-the-art review. Diagnostics. 2023;13:625.
54. Wang H, Cao J, Fan H, Huang J, Zhang H, Ling W. Compared with CT/MRI LI-RADS, whether CEUS LI-RADS is worth popularizing in diagnosis of hepatocellular carcinoma? Quant Imaging Med Surg. 2023;13:4919-32.
55. Wilson SR, Burns PN. Microbubble-enhanced US in body imaging: what role? Radiology. 2010;257:24-39.
56. Zhang J, Yu Y, Li Y, Wei L. Diagnostic value of contrast-enhanced ultrasound in hepatocellular carcinoma: a meta-analysis with evidence from 1998 to 2016. Oncotarget. 2017;8:75418-26.
57. Hai Y, Savsani E, Chong W, Eisenbrey J, Lyshchik A. Meta-analysis and systematic review of contrast-enhanced ultrasound in evaluating the treatment response after locoregional therapy of hepatocellular carcinoma. Abdom Radiol. 2021;46:5162-79.
58. Dietrich CF, Nolsøe CP, Barr RG, et al. Guidelines and good clinical practice recommendations for contrast-enhanced ultrasound (CEUS) in the liver-update 2020 WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultrasound Med Biol. 2020;46:2579-604.
59. Bartolotta TV, Taibbi A, Midiri M, Lagalla R. Contrast-enhanced ultrasound of hepatocellular carcinoma: where do we stand? Ultrasonography. 2019;38:200-14.
60. Nakai M, Sato M, Sahara S, et al. Radiofrequency ablation assisted by real-time virtual sonography and CT for hepatocellular carcinoma undetectable by conventional sonography. Cardiovasc Intervent Radiol. 2009;32:62-9.
61. Huang J, Chen W, Yao S. Assessing diagnostic value of contrast-enhanced ultrasound and contrast-enhanced computed tomography in detecting small hepatocellular carcinoma: a meta-analysis. Medicine. 2017;96:e7555.
63. Wicks JS, Dale BS, Ruffolo L, et al. Comparable and complimentary modalities for treatment of small-sized HCC: surgical resection, radiofrequency ablation, and microwave ablation. J Clin Med. 2023;12:5006.
64. Dong Y, Qiu Y, Yang D, et al. Potential application of dynamic contrast enhanced ultrasound in predicting microvascular invasion of hepatocellular carcinoma. Clin Hemorheol Microcirc. 2021;77:461-9.
65. Chernyak V, Fowler KJ, Do RKG, et al. LI-RADS: looking back, looking forward. Radiology. 2023;307:e222801.
66. Cai WJ, Ying M, Zheng RQ, et al. Contrast-enhanced ultrasound liver imaging reporting and data system in hepatocellular carcinoma ≤ 5 cm: biological characteristics and patient outcomes. Liver Cancer. 2023;12:356-71.
67. Lyshchik A, Kono Y, Dietrich CF, et al. Contrast-enhanced ultrasound of the liver: technical and lexicon recommendations from the ACR CEUS LI-RADS working group. Abdom Radiol. 2018;43:861-79.
68. Tong J, Tan Y, Ouyang W, Chang H. Targeting immune checkpoints in hepatocellular carcinoma therapy: toward combination strategies with curative potential. Exp Hematol Oncol. 2025;14:65.
69. Brooks JA, Kallenbach M, Radu IP, et al. Artificial intelligence for contrast-enhanced ultrasound of the liver: a systematic review. Digestion. 2025;106:227-44.
70. Abenavoli L, Scarlata GGM, Gambardella ML, et al. Combined model for the diagnosis of hepatocellular carcinoma: a pilot study comparing the liver to spleen volume ratio and liver vein to cava attenuation. J Clin Med. 2025;14:4306.
